New Capabilities for Medical Affairs, Market Research, and Commercial Operations
EVERSANA, a leader in global commercialization services for the life sciences industry, announced a significant expansion of its AI-powered commercialization platform. Originally designed to streamline marketing agency operations, the platform now provides comprehensive support for medical affairs, market research, MLR automation, and broader commercial functions.
This evolution marks a shift for pharmaceutical and biotech organizations moving beyond isolated AI pilots. EVERSANA’s platform enables companies to scale AI across their operational models while maintaining the strict governance and scientific rigor required in highly regulated healthcare environments.
At the heart of the platform is EVERSANA’s AI Agency, which integrates agentic AI orchestration, workflow automation, and enterprise data capabilities. These tools allow teams to accelerate content development, manage enterprise knowledge more effectively, and automate complex commercial workflows.
The pharmaceutical industry has reached an inflection point,” said Mark Thierer, Chief Executive Officer, EVERSANA. “Organizations are moving beyond isolated AI pilots and looking for practical ways to scale AI across commercialization. We’re helping clients take meaningful steps toward a more connected, efficient and AI-enabled operating model that complements human expertise while maintaining the governance and compliance our industry demands.
The company is also developing further capabilities for market access, patient services, and sales enablement. EVERSANA will showcase the expanded platform at an exclusive industry event in New York on August 27, 2026.
